Enveric Biosciences, Inc. (ENVB) - 10-K Summary
Business Context and Reporting Period
Company: Enveric Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Enveric is a pre-revenue biotechnology company developing next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The company focuses on non-hallucinogenic compounds derived from psychedelic-inspired molecules. Its lead candidate, EB-003 (EVM301 Series), is a novel DMT derivative currently in preclinical development targeting depression and anxiety. The company also unveiled the EVM401 Series in February 2025 to broaden its pipeline for addiction and neuropsychiatric disorders.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,771,987) | $(9,574,987) |
| Accumulated Deficit | $(114,846,492) | $(106,074,505) |
| Cash and Cash Equivalents (Year End) | $4,677,491 | $2,241,026 |
| Working Capital | $4,018,307 | $1,244,848 |
| Net Cash Used in Operating Activities | $(8,141,543) | $(7,726,139) |
| Net Cash Provided by Financing Activities | $10,579,507 | $7,673,834 |
Note: The company has no debt obligations listed in the balance sheet. Liquidity is maintained through equity financing.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately 9% to $8.77 million in 2025 from $9.63 million in 2024.
- General & Administrative (G&A): Decreased by 10% ($661k) primarily due to reductions in legal fees, director fees, and stock-based compensation, partially offset by a $434k increase in marketing expenses.
- Research & Development (R&D): Decreased slightly by 2% ($60k) driven by reduced salaries and CRO costs following the completion of an Australian R&D project, offset by a $1.3 million increase in consulting fees.
- Depreciation & Amortization: Decreased by 40% to $201k due to the full amortization of intangible assets in Q1 2025.
- Capital Structure: The company executed two reverse stock splits in 2025 (1-for-15 in January and 1-for-12 in October) to maintain Nasdaq listing compliance. Outstanding shares increased significantly due to multiple equity raises and warrant exercises.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $114.8 million and requires additional capital to sustain operations for the next 12 months. Current cash on hand is insufficient to meet operating needs without further financing.
- Financing Activity: The company raised approximately $10.5 million in 2025 through public offerings, ATM sales, and warrant inducement transactions. Subsequent to year-end (Jan/Feb 2026), the company raised an additional ~$2.8 million via a registered direct offering and ATM sales.
- Internal Controls: The company identified a material weakness in internal control over financial reporting as of December 31, 2025, primarily due to insufficient segregation of duties and limited personnel. Remediation efforts are underway.
- Regulatory Risks: Product candidates involve psychedelic-inspired compounds, subjecting the company to strict DEA and FDA regulations regarding controlled substances. There is uncertainty regarding the scheduling of these compounds and the timeline for regulatory approval.
- Intellectual Property: The company out-licensed its EVM201 Series (EB-002) to MycoMedica Life Sciences in late 2024 for an upfront payment and potential milestones. No revenue was recognized from this in 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $4.7 million cash balance against the burn rate of ~$8.1 million annually to confirm the timeline for the next capital raise.
- Going Concern Status: Review the auditor's explanatory paragraph regarding the substantial doubt on the company's ability to continue operations.
- Internal Control Remediation: Monitor progress on fixing the material weakness regarding segregation of duties to ensure future financial reporting reliability.
- Regulatory Pathway: Assess the specific regulatory hurdles for EB-003, particularly regarding DEA scheduling and the timeline for IND filing.
- Dilution Risk: Evaluate the impact of outstanding warrants (962,124 shares) and recent equity issuances on shareholder dilution.